Global Psoriasis Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 96

Report ID: 19351

Psoriasis is considered to be a persistent skin disorder that is characterized mainly by skin irritation and scaly rashes where the skin cells multiply up to 10 times faster than normal. Psoriasis majorly affects the knees, elbows, and scalp. The major objective of the therapy for this disease is to stop the skin cells from growing so quickly. The therapeutic approach for psoriasis depends upon the severity and amount of skin affected by the same.
In 2018, the global Psoriasis Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Psoriasis Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Psoriasis Therapeutics development in United States, Europe and China.

The key players covered in this study
Astellas Pharma Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
F. Hofffmann-La Roche
GlaxoSmithKline plc
Merck & Co., Inc.
Valeant Pharmaceuticals International, Inc.
Biocon Limited
Eli Lilly and Company
G & W Laboratories Inc.

Market segment by Type, the product can be split into
TNF Inhibitors
PDE4 Inhibitors
Interleukin Blockers
Others

Market segment by Application, split into
Oral
Parenteral
Topical

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Psoriasis Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Psoriasis Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Psoriasis Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Psoriasis Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 TNF Inhibitors
1.4.3 PDE4 Inhibitors
1.4.4 Interleukin Blockers
1.4.5 Others
1.5 Market by Application
1.5.1 Global Psoriasis Therapeutics Market Share by Application (2014-2025)
1.5.2 Oral
1.5.3 Parenteral
1.5.4 Topical
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Psoriasis Therapeutics Market Size
2.2 Psoriasis Therapeutics Growth Trends by Regions
2.2.1 Psoriasis Therapeutics Market Size by Regions (2014-2025)
2.2.2 Psoriasis Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Psoriasis Therapeutics Market Size by Manufacturers
3.1.1 Global Psoriasis Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Psoriasis Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Psoriasis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Psoriasis Therapeutics Key Players Head office and Area Served
3.3 Key Players Psoriasis Therapeutics Product/Solution/Service
3.4 Date of Enter into Psoriasis Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Psoriasis Therapeutics Market Size by Type (2014-2019)
4.2 Global Psoriasis Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Psoriasis Therapeutics Market Size (2014-2019)
5.2 Psoriasis Therapeutics Key Players in United States
5.3 United States Psoriasis Therapeutics Market Size by Type
5.4 United States Psoriasis Therapeutics Market Size by Application

6 Europe
6.1 Europe Psoriasis Therapeutics Market Size (2014-2019)
6.2 Psoriasis Therapeutics Key Players in Europe
6.3 Europe Psoriasis Therapeutics Market Size by Type
6.4 Europe Psoriasis Therapeutics Market Size by Application

7 China
7.1 China Psoriasis Therapeutics Market Size (2014-2019)
7.2 Psoriasis Therapeutics Key Players in China
7.3 China Psoriasis Therapeutics Market Size by Type
7.4 China Psoriasis Therapeutics Market Size by Application

8 Japan
8.1 Japan Psoriasis Therapeutics Market Size (2014-2019)
8.2 Psoriasis Therapeutics Key Players in Japan
8.3 Japan Psoriasis Therapeutics Market Size by Type
8.4 Japan Psoriasis Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Psoriasis Therapeutics Market Size (2014-2019)
9.2 Psoriasis Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Psoriasis Therapeutics Market Size by Type
9.4 Southeast Asia Psoriasis Therapeutics Market Size by Application

10 India
10.1 India Psoriasis Therapeutics Market Size (2014-2019)
10.2 Psoriasis Therapeutics Key Players in India
10.3 India Psoriasis Therapeutics Market Size by Type
10.4 India Psoriasis Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Psoriasis Therapeutics Market Size (2014-2019)
11.2 Psoriasis Therapeutics Key Players in Central & South America
11.3 Central & South America Psoriasis Therapeutics Market Size by Type
11.4 Central & South America Psoriasis Therapeutics Market Size by Application

12 International Players Profiles
12.1 Astellas Pharma Inc.
12.1.1 Astellas Pharma Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Psoriasis Therapeutics Introduction
12.1.4 Astellas Pharma Inc. Revenue in Psoriasis Therapeutics Business (2014-2019)
12.1.5 Astellas Pharma Inc. Recent Development
12.2 AstraZeneca plc
12.2.1 AstraZeneca plc Company Details
12.2.2 Company Description and Business Overview
12.2.3 Psoriasis Therapeutics Introduction
12.2.4 AstraZeneca plc Revenue in Psoriasis Therapeutics Business (2014-2019)
12.2.5 AstraZeneca plc Recent Development
12.3 Boehringer Ingelheim GmbH
12.3.1 Boehringer Ingelheim GmbH Company Details
12.3.2 Company Description and Business Overview
12.3.3 Psoriasis Therapeutics Introduction
12.3.4 Boehringer Ingelheim GmbH Revenue in Psoriasis Therapeutics Business (2014-2019)
12.3.5 Boehringer Ingelheim GmbH Recent Development
12.4 F. Hofffmann-La Roche
12.4.1 F. Hofffmann-La Roche Company Details
12.4.2 Company Description and Business Overview
12.4.3 Psoriasis Therapeutics Introduction
12.4.4 F. Hofffmann-La Roche Revenue in Psoriasis Therapeutics Business (2014-2019)
12.4.5 F. Hofffmann-La Roche Recent Development
12.5 GlaxoSmithKline plc
12.5.1 GlaxoSmithKline plc Company Details
12.5.2 Company Description and Business Overview
12.5.3 Psoriasis Therapeutics Introduction
12.5.4 GlaxoSmithKline plc Revenue in Psoriasis Therapeutics Business (2014-2019)
12.5.5 GlaxoSmithKline plc Recent Development
12.6 Merck & Co., Inc.
12.6.1 Merck & Co., Inc. Company Details
12.6.2 Company Description and Business Overview
12.6.3 Psoriasis Therapeutics Introduction
12.6.4 Merck & Co., Inc. Revenue in Psoriasis Therapeutics Business (2014-2019)
12.6.5 Merck & Co., Inc. Recent Development
12.7 Valeant Pharmaceuticals International, Inc.
12.7.1 Valeant Pharmaceuticals International, Inc. Company Details
12.7.2 Company Description and Business Overview
12.7.3 Psoriasis Therapeutics Introduction
12.7.4 Valeant Pharmaceuticals International, Inc. Revenue in Psoriasis Therapeutics Business (2014-2019)
12.7.5 Valeant Pharmaceuticals International, Inc. Recent Development
12.8 Biocon Limited
12.8.1 Biocon Limited Company Details
12.8.2 Company Description and Business Overview
12.8.3 Psoriasis Therapeutics Introduction
12.8.4 Biocon Limited Revenue in Psoriasis Therapeutics Business (2014-2019)
12.8.5 Biocon Limited Recent Development
12.9 Eli Lilly and Company
12.9.1 Eli Lilly and Company Company Details
12.9.2 Company Description and Business Overview
12.9.3 Psoriasis Therapeutics Introduction
12.9.4 Eli Lilly and Company Revenue in Psoriasis Therapeutics Business (2014-2019)
12.9.5 Eli Lilly and Company Recent Development
12.10 G & W Laboratories Inc.
12.10.1 G & W Laboratories Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Psoriasis Therapeutics Introduction
12.10.4 G & W Laboratories Inc. Revenue in Psoriasis Therapeutics Business (2014-2019)
12.10.5 G & W Laboratories Inc. Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details